|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1100 NEW YORK AVENUE, NW, #440 E |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 69674-12
|
||||||||
|
6. House ID# 357890000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Laura Weidner |
Date | 10/23/2017 7:56:41 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
- Department of Defense Appropriations Act, 2018, support $10 million for the Multiple Sclerosis Congressionally Directed Medical Research Program (CDMRP).
- Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, 2018, support a $2 billion increase above FY 2017 levels for the NIH; Support $5million for the Centers for Disease Control and Prevention to implement the National Neurological Conditions Surveillance System; $150 million for the Patient Centered Outcomes Research Institute (PCORI); $5 million for the Lifespan Respite Care Program; an increase over our recommended FY17 funding level of $13.067 billion for the SSAs administrative budget; and $364 million for the Agency for Healthcare Research and Quality (AHRQ).
- Department of Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2018, support $2.8 billion for the FDA; the $500 million provided for targeted programs at the FDA by the 21st Century Cures Act; and an additional $1.35 billion in medical product user fees.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Weidner |
|
|
|
John |
Wylam |
|
|
|
Leslie |
Ritter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
-H.R. 1628, oppose the American Health Care Act, Better Care Reconciliation Act and Obamacare Repeal Reconciliation Act.
-H.R. 750, support passage of the Ensuring Access to Quality Complex Rehabilitation Technology Act.
-H.R. 1361/S. 486/H.R. 3730, support passage to protect access to complex rehabilitative technology accessories.
-H.R. 2535/S. 1188, Lifespan Respite Care Reauthorization Act, support reauthorization of the Lifespan Respite Care Program.
-H.R. 807/S.253 , Medicare Access to Rehabilitation Services Act, support passage.
-H.R. 2439/S. 1131, FAIR Drug Pricing Act, support passage.
-H.R. 2430/ S. 934, FDA Reauthorization Act of 2017, support passage.
- H.R. 2212/ S. 974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act), support passage.
- H.R. 2051, Fair Access for Safe and Timely Generics Act of 2017 (FAST Generics Act), support passage.
-H.R. 2123/S. 925 Veterans E-Health and Telemedicine Support Act of 2017, support passage.
-H.R. 2556/S. 1016 Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017, support passage.
-S. 870 Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017, support passage.
-S. 1028/H.R. 3759, RAISE Family Caregivers Act, support passage.
-HR 2575, Beneficiary Enrollment Notification and Eligibility Simplification (BENES) Act, support passage.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Weidner |
|
|
|
Kimberly |
Calder |
|
|
|
Leslie |
Ritter |
|
|
|
John |
Wylam |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
-H.R. 1628, oppose the American Health Care Act and Better Care Reconciliation Act.
-H.R. 750, support passage of the Ensuring Access to Quality Complex Rehabilitation Technology Act.
-H.R. 1361/S. 486, support passage to protect access to complex rehabilitative technology accessories.
-H.R. 807/S.253 , Medicare Access to Rehabilitation Services Act, support passage.
-H.R. 2556/S. 1016 Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017, support passage.
-S. 870 Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017, support passage.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Weidner |
|
|
|
Leslie |
Ritter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 2810/S.1519-National Defense Authorization Act (NDAA) of 2018, oppose amendment that threatens MS Research Program through the Congressionally Directed Medical Research Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Wylam |
|
|
|
Leslie |
Ritter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
None this quarter.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Weidner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
H.R. 620, ADA Education and Reform Act, oppose passage.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Weidner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
No foreign interests.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |